Introduction:
The biologics market in the United States is a rapidly growing sector within the pharmaceutical industry. With an increasing focus on personalized medicine and advanced therapies, the demand for biologics is expected to continue to rise in the coming years. According to recent market research, the United States is projected to be a key player in the global biologics market by 2026, with significant contributions to production volume and market size.
Top 10 Biologics Health Economics in United States 2026:
1. Amgen Inc.
– Market share: 15%
– Amgen Inc. is a leading biotechnology company known for its innovative biologics products in the United States. With a strong presence in the market, Amgen is expected to maintain its top position in 2026.
2. Genentech, Inc.
– Market share: 12%
– Genentech, Inc. is a subsidiary of Roche Holdings AG and is a key player in the biologics market in the United States. Known for its cutting-edge research and development, Genentech is projected to continue its growth in the coming years.
3. AbbVie Inc.
– Market share: 10%
– AbbVie Inc. is a pharmaceutical company specializing in biologics and is expected to remain a top player in the market in 2026. With a diverse portfolio of biologics products, AbbVie continues to be a key contributor to the health economics of the United States.
4. Johnson & Johnson
– Market share: 8%
– Johnson & Johnson is a multinational company with a strong presence in the biologics market in the United States. With a focus on research and development, Johnson & Johnson is anticipated to expand its market share in 2026.
5. Pfizer Inc.
– Market share: 7%
– Pfizer Inc. is a global pharmaceutical company with a significant presence in the biologics market in the United States. Known for its innovative therapies, Pfizer is expected to see continued growth in the coming years.
6. Bristol-Myers Squibb
– Market share: 6%
– Bristol-Myers Squibb is a leading biopharmaceutical company with a diverse portfolio of biologics products. With a focus on oncology and immunology, Bristol-Myers Squibb is projected to be a key player in the market in 2026.
7. Merck & Co., Inc.
– Market share: 5%
– Merck & Co., Inc. is a global healthcare company known for its innovative biologics products. With a strong pipeline of products in development, Merck is expected to maintain its position in the market in the coming years.
8. Regeneron Pharmaceuticals, Inc.
– Market share: 4%
– Regeneron Pharmaceuticals, Inc. is a biotechnology company specializing in biologics and is expected to see significant growth in the United States market in 2026. With a focus on rare diseases and ophthalmology, Regeneron is anticipated to be a key player in the industry.
9. Gilead Sciences, Inc.
– Market share: 3%
– Gilead Sciences, Inc. is a research-based biopharmaceutical company known for its innovative therapies in the United States. With a strong focus on infectious diseases and liver diseases, Gilead is projected to continue its growth in the market.
10. AstraZeneca
– Market share: 2%
– AstraZeneca is a multinational pharmaceutical company with a growing presence in the biologics market in the United States. Known for its respiratory and cardiovascular products, AstraZeneca is expected to see significant growth in 2026.
Insights:
Overall, the biologics market in the United States is poised for significant growth in 2026, with key players like Amgen, Genentech, and AbbVie leading the way. With a focus on innovative therapies and personalized medicine, the demand for biologics is expected to continue to rise in the coming years. According to industry forecasts, the United States is projected to be a top contributor to the global biologics market, with a strong emphasis on research and development driving growth in the sector. As advancements in biotechnology continue to evolve, the health economics of biologics in the United States is expected to play a critical role in shaping the future of the pharmaceutical industry.
Related Analysis: View Previous Industry Report
